Franklin Resources Inc. Buys 573 Shares of argenx SE (NASDAQ:ARGX)

Franklin Resources Inc. grew its position in argenx SE (NASDAQ:ARGX - Free Report) by 0.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 134,591 shares of the company's stock after purchasing an additional 573 shares during the quarter. Franklin Resources Inc. owned approximately 0.22% of argenx worth $82,774,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Whipplewood Advisors LLC acquired a new stake in argenx during the 4th quarter valued at $37,000. Global Retirement Partners LLC boosted its stake in shares of argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after buying an additional 48 shares during the last quarter. Jones Financial Companies Lllp grew its stake in shares of argenx by 1,016.7% in the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after buying an additional 61 shares in the last quarter. Whittier Trust Co. of Nevada Inc. lifted its position in shares of argenx by 78.6% in the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company's stock valued at $46,000 after buying an additional 33 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its holdings in shares of argenx by 38.2% during the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock worth $47,000 after buying an additional 21 shares during the period. Institutional investors and hedge funds own 60.32% of the company's stock.

Remove Ads

argenx Stock Performance

Shares of NASDAQ:ARGX traded up $18.28 during trading hours on Tuesday, hitting $568.28. 177,895 shares of the company's stock traded hands, compared to its average volume of 298,523. The company's fifty day simple moving average is $619.46 and its two-hundred day simple moving average is $603.79. The company has a market cap of $34.53 billion, a price-to-earnings ratio of -644.97 and a beta of 0.60. argenx SE has a 52 week low of $352.77 and a 52 week high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, analysts anticipate that argenx SE will post 3.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ARGX shares. Piper Sandler raised their price objective on argenx from $620.00 to $725.00 and gave the company an "overweight" rating in a research note on Tuesday, January 7th. Truist Financial reaffirmed a "buy" rating and set a $700.00 target price (up from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Oppenheimer lifted their price objective on shares of argenx from $675.00 to $704.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. William Blair reaffirmed an "outperform" rating on shares of argenx in a research report on Friday, February 28th. Finally, HC Wainwright increased their target price on argenx from $717.00 to $720.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Three research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $687.00.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.